Getinge (GETI.B) AI Stock Analysis

• Market Cap: kr51.21B
• Dividend Yield: 2.45%
• Average Volume (3M): 644.35K
• Price to Earnings (P/E): 34.6
• Beta (1Y): 1.06
• Revenue Growth: 10.46%
• EPS Growth: -35.27%
• Country: SE
• Employees: 11,827
• Sector: Industrials
• Sector Strength: 85
• Industry: Medical - Devices
• EPS (TTM): 2.18
• Shares Outstanding: 254,152,370
• 10 Day Avg. Volume: 578,381
• 30 Day Avg. Volume: 644,348
• PEG Ratio: -1.47
• Price to Book (P/B): 1.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 26.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr222.00
• Price Target Upside: 20.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 64 Neutral
• Price Target: kr206.00 ▲(11.53%Upside)

Getinge's stock score is driven by sound financial performance, characterized by steady revenue growth and solid cash flow generation. However, increased leverage and the need for margin expansion are areas of concern. Technical indicators suggest mixed momentum, with potential overvaluation reflected in a high P/E ratio. The dividend yield provides some compensation for the valuation risk.

Getinge Business Overview & Revenue Model

Company Description

Getinge AB is a global medical technology company headquartered in Sweden, specializing in providing innovative solutions for healthcare and life sciences. The company operates primarily in three segments: Acute Care Therapies, Life Science, and Surgical Workflows. Its core products and services include advanced equipment for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, and life science research.

How the Company Makes Money

Getinge generates revenue through the sale of its medical technology products and solutions across its three primary business segments. In the Acute Care Therapies segment, the company earns income from selling advanced medical equipment and therapies used in critical care settings, such as ventilators, extracorporeal life support, and anesthesia systems. The Life Science segment contributes through the sale of sterilization, isolation, and containment solutions tailored for pharmaceutical and biomedical research industries. In the Surgical Workflows segment, Getinge makes money from providing operating room solutions, including surgical tables, lights, and integrated workflow technologies. Additionally, the company benefits from service contracts, maintenance fees, and consumable sales related to its equipment. Strategic partnerships and collaborations with healthcare providers and research institutions also play a pivotal role in expanding its market reach and enhancing its product offerings.

Getinge Financial Statement Overview

Summary

Getinge shows consistent revenue growth and maintains moderate profitability metrics. Its balance sheet is stable, though increased leverage and reduced returns on equity could pose risks. Cash flow generation remains strong despite a recent decline in free cash flow. Overall, the company's financials are sound, with areas for improvement in margin expansion and leverage management.

Income Statement

Getinge demonstrates solid profitability with a strong gross profit margin of approximately 46% and a respectable net profit margin of around 4.2% for TTM. However, both EBIT and EBITDA margins have slightly contracted compared to previous years. Revenue growth is healthy, with a year-over-year increase of 2.3% in the TTM. The company exhibits moderate revenue growth and stable profitability, though declining EBIT margins may require attention.

Balance Sheet

The balance sheet reveals a stable financial structure with an equity ratio of about 50.7%, indicating a balanced asset financing strategy. However, the debt-to-equity ratio has increased to 0.38, reflecting higher leverage compared to prior years. Return on equity stands at 4.8% for the TTM, showing a reduction from previous periods, which suggests potential challenges in generating returns on equity.

Cash Flow

Cash flow analysis indicates a decline in free cash flow growth, with a negative growth rate of approximately -24% compared to the previous annual report. The operating cash flow to net income ratio is robust at 2.57, highlighting efficient cash generation relative to net income. Despite the decline in free cash flow, the company maintains a healthy cash conversion efficiency.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
35.57B	34.76B	31.83B	28.29B	27.05B	29.82B
	Gross Profit
16.36B	16.15B	14.49B	13.41B	13.58B	14.72B
	EBIT
2.77B	2.85B	3.74B	3.63B	4.37B	4.78B
	EBITDA
6.36B	5.31B	5.93B	5.73B	6.20B	6.46B
	Net Income Common Stockholders
1.48B	1.64B	2.41B	2.49B	2.97B	3.24B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.20B	2.96B	2.73B	5.68B	4.08B	6.06B
	Total Assets
60.27B	63.92B	53.59B	52.03B	44.55B	45.01B
	Total Debt
11.48B	10.73B	8.08B	5.82B	4.31B	10.21B
	Net Debt
7.28B	7.77B	5.41B	148.00M	230.00M	4.15B
	Total Liabilities
29.52B	30.71B	23.18B	21.58B	19.38B	23.53B
	Stockholders Equity
30.55B	33.01B	30.17B	30.04B	24.75B	21.02B
Cash Flow		Free Cash Flow
2.48B	3.27B	1.60B	2.23B	5.63B	6.15B
	Operating Cash Flow
3.80B	4.58B	2.96B	3.37B	6.56B	7.20B
	Investing Cash Flow
-4.64B	-4.55B	-6.54B	-1.47B	-1.33B	-1.99B
	Financing Cash Flow
1.94B	504.00M	511.00M	-500.00M	-7.24B	-297.00M

Getinge Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 184.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GETI.B, the sentiment is Negative. The current price of 184.7 is below the 20-day moving average (MA) of 187.74, below the 50-day MA of 187.74, and below the 200-day MA of 194.12, indicating a bearish trend. The MACD of -0.92 indicates Positive momentum. The RSI at 43.35 is Neutral, neither overbought nor oversold. The STOCH value of 37.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:GETI.B.

Getinge Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	72 Outperform	kr1.18B	36.43	10.11%	―	2.53%	-44.90%
Sector *	66 Neutral	$4.50B	12.26	5.40%	3.65%	4.17%	-12.02%
SECT.B	66 Neutral	kr61.97B	108.61	32.07%	0.35%	15.54%	39.12%
GETI.B	64 Neutral	kr51.21B	34.62	4.70%	2.45%	10.46%	-35.27%
EKTA.B	64 Neutral	kr18.26B	77.36	2.43%	5.03%	-0.57%	-81.68%
SEDANA	55 Neutral	kr1.03B	―	-5.61%	―	13.66%	-139.90%
BACTI.B	46 Neutral	kr1.04B	―	-7.30%	―	23.51%	80.47%